
HCC
Latest News
Latest Videos

More News



Nivolumab (Opdivo) has been granted a priority review designation by the FDA for use as a treatment for patients with hepatocellular carcinoma following prior sorafenib (Nexavar).

Long-Term Strategies in Advanced HCC





Later Line Therapeutic Decisions in Metastatic HCC







Later Line Therapeutic Decisions in Metastatic HCC





Current guidelines recommend waiting 6 months before resecting a large hepatocellular adenoma to prevent a transformation to a malignant tumor; however, a recent study suggests that waiting longer could benefit some patients.

Tim F. Greten, MD, discusses the evolving role of immunotherapy in HCC.

Nivolumab (Opdivo) demonstrated promise as a second-line therapy for patients with hepatocellular carcinoma (HCC), according to results of the CheckMate-040 trial presented at the 2017 International Liver Congress.

An overview of FDA news that happened in April.

Regorafenib has been approved by the FDA as a second-line treatment for patients with unresectable hepatocellular carcinoma who have previously received sorafenib.






























